– UK, Oxford – Oxford Biomedica plc (LON: OXB), a leading gene and cell therapy group, today announced that Dr Roch Doliveux will become Non-Executive Chairman of the Group with effect from 24 June 2020.
“Roch has extensive global experience with life science and healthcare companies including in leadership, strategy, financials, Board governance and has a passion for patient centricity. We are delighted that Roch will lead the Board through the next phase at Oxford Biomedica and we look forward to him joining us in June.” said CEO John Dawson.
Dr Lorenzo Tallarigo informed the Group on 18 March 2020 of his intention to retire from Oxford Biomedica’s Board. Dr Tallarigo will step down as Chairman at the AGM on 23 June 2020.
John Dawson added: “On behalf of the Group I thank Lorenzo for his leadership of the Board over the past four years and we wish him every success for his future.”
Dr. Lorenzo Tallarigo commented: “I am proud of the achievements the group has made over the past four years including the execution of its now successful strategy, the build-out of it market-leading capabilities, several major new partnerships and resultant share price performance. This progress has led to significant growth in the Group’s value and I now hand over the reins to Roch of a significantly transformed business with enormous global potential. I wish Roch and the team continued success in the years ahead.”
About Dr. Roch Doliveux
Dr. Doliveux is currently the Chairman of the Board of Directors at Pierre Fabre S.A and a Non-Executive Director at Stryker Corporation and UCB SA. Dr Doliveux was previously the CEO of UCB SA for ten years during which time he transformed the company from a diversified chemical group into a global biopharmaceutical leader. Prior to that, he worked at Schering-Plough International, Inc from 1990-2003 and at Ciba-Geigy AG from 1982.
Dr Doliveux is also Chairman of the GLG Healthcare Institute, a community of senior executives for experience sharing and learning. He was Vice-President of the European Federation of Pharmaceutical Association Board and Chairman of the Board of the Innovative Medicines Initiative which is the largest healthcare public-private partnership in the world. Dr Doliveux also chairs the Caring Entrepreneurship Fund, a philanthropic initiative which he created in 2008 which supports entrepreneurship in health and wellness.
Dr Roch Doliveux said: “I am delighted to be joining Oxford Biomedica at a time when the cell and gene therapy sector is growing so rapidly. The Group is clearly at the forefront of innovation in this field and I look forward to getting to know the science and helping to realise the potential of this world-leading technology for saving and bettering the lives of patients.”
Dr Roch Doliveux is a Veterinary Surgeon by training and has an MBA from INSEAD.
About Oxford Biomedica
Oxford Biomedica (LON:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries have built a sector leading lentiviral vector delivery platform, which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people.
For more information : https://www.oxfordbiomedica.co.uk
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.